236 related articles for article (PubMed ID: 34750637)
1. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
[TBL] [Abstract][Full Text] [Related]
2. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
3. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
4. An Integrated Analysis of Dostarlimab Immunogenicity.
Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A
AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
[TBL] [Abstract][Full Text] [Related]
6. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
7. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
9. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Yap TA; Bessudo A; Hamilton E; Sachdev J; Patel MR; Rodon J; Evilevitch L; Duncan M; Guo W; Kumar S; Lu S; Dezube BJ; Gabrail N
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35332062
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
[TBL] [Abstract][Full Text] [Related]
11. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
14. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
[TBL] [Abstract][Full Text] [Related]
16. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
17. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Keam B; Ock CY; Kim TM; Oh DY; Kang WK; Park YH; Lee J; Lee JH; Ahn YH; Kim HJ; Chang SK; Park J; Choi JY; Song YJ; Park YS
Invest New Drugs; 2021 Dec; 39(6):1624-1632. PubMed ID: 34268711
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
